| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Modalis Therapeutics Corp
Modalis Therapeutics Corp
TSE:4883
Modalis Therapeutics Corp
Cash & Cash Equivalents
Modalis Therapeutics Corp
Cash & Cash Equivalents Peer Comparison
2160
4587
4974
2929
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Modalis Therapeutics Corp
TSE:4883
|
Cash & Cash Equivalents
¥1.9B
|
CAGR 3-Years
-30%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
GNI Group Ltd
TSE:2160
|
Cash & Cash Equivalents
¥20.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
34%
|
CAGR 10-Years
15%
|
|
|
PeptiDream Inc
TSE:4587
|
Cash & Cash Equivalents
¥27.3B
|
CAGR 3-Years
33%
|
CAGR 5-Years
35%
|
CAGR 10-Years
24%
|
|
|
Takara Bio Inc
TSE:4974
|
Cash & Cash Equivalents
¥35.4B
|
CAGR 3-Years
11%
|
CAGR 5-Years
16%
|
CAGR 10-Years
5%
|
|
|
Pharma Foods International Co Ltd
TSE:2929
|
Cash & Cash Equivalents
¥17B
|
CAGR 3-Years
44%
|
CAGR 5-Years
33%
|
CAGR 10-Years
33%
|
|
J
|
Japan Tissue Engineering Co Ltd
TSE:7774
|
Cash & Cash Equivalents
¥4.3B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
13%
|
See Also
What is Modalis Therapeutics Corp's Cash & Cash Equivalents?
Cash & Cash Equivalents
1.9B
JPY
Based on the financial report for Dec 31, 2023, Modalis Therapeutics Corp's Cash & Cash Equivalents amounts to 1.9B JPY.
What is Modalis Therapeutics Corp's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
9%
Over the last year, the Cash & Cash Equivalents growth was -36%. The average annual Cash & Cash Equivalents growth rates for Modalis Therapeutics Corp have been -30% over the past three years , 9% over the past five years .
You don't have any saved screeners yet
